Azurity Pharmaceuticals clinical trials

Also known as CutisPharma.

Part of QHP Capital.

The registry lists 78 studies whose lead sponsor is Azurity Pharmaceuticals or one of 4 companies grouped under it. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 15, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 78. Browse all 78 →

• Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset SeizuresNot yet recruitingNCT06534502Phase 4
• A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)RecruitingNCT03619850Phase 3

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric SubjectsRecruitingNCT03893045Phase 3

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• Ambulatory Blood Pressure Monitoring (ABPM) Study in Hypogonadal MenNot yet recruitingNCT07328542Phase 4
• Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe PreeclampsiaTerminatedNCT03008616Phase 2/3

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy AdultsTerminatedNCT04593784Phase 2

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD)CompletedNCT00707876Phase 2

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• Vigilant ObservatIon of GlIadeL WAfer ImplaNT RegistryCompletedNCT02684838

  Sponsor listed in the registry: Arbor Pharmaceuticals, Inc. · Arbor Pharmaceuticals, Inc. — acquired company within the Azurity Pharmaceuticals group

• Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCTCompletedNCT03172910Phase 2

  Sponsor listed in the registry: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. · First submitted before Perosphere Pharmaceuticals Inc became part of Azurity Pharmaceuticals

• Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCTCompletedNCT03288454Phase 2

  Sponsor listed in the registry: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. · First submitted before Perosphere Pharmaceuticals Inc became part of Azurity Pharmaceuticals

• An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With HypertensionCompletedNCT02235909Phase 3

  Sponsor listed in the registry: Arbor Pharmaceuticals, Inc. · Arbor Pharmaceuticals, Inc. — acquired company within the Azurity Pharmaceuticals group

• Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine SulfateCompletedNCT03659929Phase 3

  Sponsor listed in the registry: Arbor Pharmaceuticals, Inc. · Arbor Pharmaceuticals, Inc. — acquired company within the Azurity Pharmaceuticals group

• An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug UsersCompletedNCT06097676Phase 4

  Sponsor listed in the registry: Arbor Pharmaceuticals, Inc. · Arbor Pharmaceuticals, Inc. — acquired company within the Azurity Pharmaceuticals group

• Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid UsersCompletedNCT06247488Phase 4

  Sponsor listed in the registry: Arbor Pharmaceuticals, Inc. · Arbor Pharmaceuticals, Inc. — acquired company within the Azurity Pharmaceuticals group

• A Trial Comparing Ferumoxytol to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney DiseaseCompletedNCT01052779Phase 2

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)CompletedNCT02694978Phase 3

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm DeliveryCompletedNCT01004029Phase 3

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm BirthCompletedNCT01146990

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal WomenCompletedNCT02940522Phase 1

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney DiseaseTerminatedNCT01264679Phase 3

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Nondialysis-Dependent Chronic Kidney DiseaseTerminatedNCT01155388Phase 3

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal WomenTerminatedNCT02937766Phase 3

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• A Trial Comparing Ferumoxytol With Iron Sucrose for the Treatment of Iron Deficiency AnemiaCompletedNCT01114204Phase 3

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• Compare Efficacy/Safety of Repeat Doses of Ferumoxytol With Iron Sucrose in CKD Subjects With IDA and on HemodialysisCompletedNCT01227616Phase 4

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency AnemiaCompletedNCT01114217Phase 3

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency AnemiaCompletedNCT01114139Phase 3

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• Phase I Rising-dose Study to Assess Tolerability, Safety, Pharmacokinetics, Pharmacodynamics of AR09TerminatedNCT02027155Phase 1

  Sponsor listed in the registry: Arbor Pharmaceuticals, Inc. · Arbor Pharmaceuticals, Inc. — acquired company within the Azurity Pharmaceuticals group

• A Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and WomenCompletedNCT00360425Phase 1

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney DiseaseTerminatedNCT01155375Phase 3

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Hemodialysis PatientsCompletedNCT00233597Phase 3

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With ZofranCompletedNCT03973047Phase 1

  Sponsor listed in the registry: AMAG Pharmaceuticals, Inc. · First submitted before AMAG Pharmaceuticals, Inc. became part of Azurity Pharmaceuticals

• An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLSStatus unknownNCT02560766Phase 4

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLSStatus unknownNCT02633683Phase 4

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment StudyCompletedNCT01668667Phase 4

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease SubjectsCompletedNCT00914602Phase 1/2

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLSWithdrawnNCT02633657Phase 1

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• A Study to Evaluate the Effect of Gabapentin on Cardiac Repolarization in Healthy VolunteersCompletedNCT01516372Phase 1

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• A Safety and Efficacy Study of XP19986 in Subjects With Spasticity Due to Spinal Cord InjuryCompletedNCT00557973Phase 2

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple SclerosisCompletedNCT01359566Phase 3

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERDCompletedNCT00557401Phase 2

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back SpasmsCompletedNCT00817986Phase 2

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)CompletedNCT00978016Phase 2

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease SubjectsCompletedNCT01171313Phase 2

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• Crossover Study to Evaluate the Efficacy of AR11 in Pediatric Patients With ADHD in a Laboratory Classroom SettingCompletedNCT01986062Phase 4

  Sponsor listed in the registry: Arbor Pharmaceuticals, Inc. · Arbor Pharmaceuticals, Inc. — acquired company within the Azurity Pharmaceuticals group

• Pharmacokinetics of Ultra-Rapid-Acting Insulin Lispro (URAL) in Type 1 Diabetes MellitusWithdrawnNCT02206568Phase 1

  Sponsor listed in the registry: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. · First submitted before Perosphere Pharmaceuticals Inc became part of Azurity Pharmaceuticals

• Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of EdoxabanCompletedNCT01826266Phase 1

  Sponsor listed in the registry: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. · First submitted before Perosphere Pharmaceuticals Inc became part of Azurity Pharmaceuticals

• Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With EdoxabanCompletedNCT02207257Phase 2

  Sponsor listed in the registry: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. · First submitted before Perosphere Pharmaceuticals Inc became part of Azurity Pharmaceuticals

• PK and PD of Single, Escalating Doses of PER977 Following EnoxaparinCompletedNCT02206100Phase 1/2

  Sponsor listed in the registry: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. · First submitted before Perosphere Pharmaceuticals Inc became part of Azurity Pharmaceuticals

• Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following HeparinCompletedNCT02206087Phase 1/2

  Sponsor listed in the registry: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. · First submitted before Perosphere Pharmaceuticals Inc became part of Azurity Pharmaceuticals

• Variability of Whole Blood Clotting Time Measurements in Ex Vivo Human Blood Samples Spiked With AnticoagulantsCompletedNCT03296982

  Sponsor listed in the registry: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. · First submitted before Perosphere Pharmaceuticals Inc became part of Azurity Pharmaceuticals